Abiopharma

🔍 Chan Andrew C. (Executive)

Company: Corvus Pharmaceuticals, Inc. (CRVS)

Report Date: 2026-04-23

Detailed Transactions and Holdings:

• Acquired 30,000 shares of Stock Option (Right to Buy) at $16.02 per share (Derivative)
  Date: 2026-04-23 | Code: A | Expires: 2036-04-23 | equity_swap_involved: 0 | shares_owned_after: 30,000.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from April 23, 2026, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.